Complement factor C5a induces atherosclerotic plaque disruptions

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 10, 2014, Pages 2020-2030

  Wezel, Anouk ^a,b   de Vries, Margreet R ^b   Lagraauw, H Maxime ^a   Foks, Amanda C ^a   Kuiper, Johan ^a   Quax, Paul H A ^b   Bot, Ilze ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Atherosclerosis; C5a; Plaque rupture

Indexed keywords

APOLIPOPROTEIN E; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; MESSENGER RNA;

ANIMAL; APOPTOSIS; CELL CULTURE; ENZYME IMMUNOASSAY; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PLAQUE, ATHEROSCLEROTIC; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE CELL; VASCULAR ENDOTHELIUM;

ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; CELLS, CULTURED; COMPLEMENT C5A; ENDOTHELIUM, VASCULAR; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; PLAQUE, ATHEROSCLEROTIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ANAPHYLATOXIN C5A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84908077470     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12357     Document Type: Article

References (47)

1. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001; 104: 503-16.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125: e2-220.
3. Von der Thüsen JH, van Vlijmen BJM, Hoeben RC, et al. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation. 2002; 105: 2064-70.
4. Stoneman VEA, Bennett MR. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci. 2004; 107: 343-54.
5. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med. 2008; 263: 517-27.
6. Oksjoki R, Kovanen PT, Meri S, et al. Function and regulation of the complement system in cardiovascular diseases. Front Biosci. 2007; 12: 4696-708.
7. Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008; 19: 478-82.
8. Speidl WS, Kastl SP, Huber K, et al. Complement in atherosclerosis: friend or foe? J Thromb Haemost. 2011; 9: 428-40.
9. Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost. 2009; 102: 564-72.
10. Haas P-J, van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res. 2007; 37: 161-75.
11. Guo R-F, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005; 23: 821-52.
12. Buono C, Come CE, Witztum JL, et al. Influence of C3 deficiency on atherosclerosis. Circulation. 2002; 105: 3025-31.
13. Conroy A, Serghides L, Finney C, et al. C5a enhances dysregulated inflammatory and angiogenic responses to malaria in vitro: potential implications for placental malaria. PLoS ONE. 2009; 4: e4953.
14. De Vries MR, Wezel A, Schepers A, et al. Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res. 2013; 97: 311-20.
15. Manthey HD, Thomas AC, Shiels IA, et al. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 2011; 25: 2447-55.
16. Shagdarsuren E, Bidzhekov K, Mause SF, et al. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. Circulation. 2010; 122: 1026-36.
17. Speidl WS, Exner M, Amighi J, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J. 2005; 26: 2294-9.
18. De Vries MR, Niessen HWM, Löwik CWGM, et al. Plaque rupture complications in murine atherosclerotic vein grafts can be prevented by TIMP-1 overexpression. PLoS ONE. 2012; 7: e47134.
19. Bot I, de Jager SCA, Zernecke A, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation. 2007; 115: 2516-25.
20. Bot M, de Jager SCA, MacAleese L, et al. Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation. J Lipid Res. 2013; 54: 1265-74.
21. Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 2008; 102: 209-17.
22. Zhao Y, Pennings M, Hildebrand RB, et al. Enhanced foam cell formation, atherosclerotic lesion development, and inflammation by combined deletion of ABCA1 and SR-BI in Bone marrow-derived cells in LDL receptor knockout mice on western-type diet. Circ Res. 2010; 107: e20-31.
23. Lammers B, Zhao Y, Hoekstra M, et al. Augmented atherogenesis in LDL receptor deficient mice lacking both macrophage ABCA1 and ApoE. PLoS ONE. 2011; 6: e26095.
24. Meurs I, Lammers B, Zhao Y, et al. The effect of ABCG1 deficiency on atherosclerotic lesion development in LDL receptor knockout mice depends on the stage of atherogenesis. Atherosclerosis. 2012; 221: 41-7.
25. Michon IN, Hauer AD, von der Thüsen JH, et al. Targeting of peptides to restenotic vascular smooth muscle cells using phage display in vitro and in vivo. Biochim Biophys Acta. 2002; 1591: 87-97.
26. Garlanda C, Parravicini C, Sironi M, et al. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci USA. 1994; 91: 7291-5.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162: 156-9.
28. Bosmann M, Haggadone MD, Hemmila MR, et al. Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages. J Immunol. 2012; 188: 5086-93.
29. Albrecht EA, Sarma JV, Ward PA. Activation by C5a of endothelial cell caspase 8 and cFLIP. Inflamm Res. 2009; 58: 30-7.
30. Flierl MA, Rittirsch D, Chen AJ, et al. The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS ONE. 2008; 3: e2560.
31. Pavlovski D, Thundyil J, Monk PN, et al. Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J. 2012; 26: 3680-90.
32. Den Dekker WK, Tempel D, Bot I, et al. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler Thromb Vasc Biol. 2012; 32: 1960-9.
33. Lindstedt KA, Kovanen PT. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr Opin Lipidol. 2004; 15: 567-73.
34. Finn AV, Nakano M, Narula J, et al. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010; 30: 1282-92.
35. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003; 41: 15S-22S.
36. Silvestre-Roig C, de Winther MP, Weber C, et al. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res. 2014; 114: 214-26.
37. Schwartz SM, Galis ZS, Rosenfeld ME, et al. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol. 2007; 27: 705-13.
38. Cullen P, Baetta R, Bellosta S, et al. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol. 2003; 23: 535-42.
39. Speidl WS, Kastl SP, Hutter R, et al. The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro. FASEB J. 2011; 25: 35-44.
40. Myoishi M, Hao H, Minamino T, et al. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation. 2007; 116: 1226-33.
41. Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001; 16: 285-92.
42. Clarke MCH, Figg N, Maguire JJ, et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006; 12: 1075-80.
43. Clarke MCH, Littlewood TD, Figg N, et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res. 2008; 102: 1529-38.
44. Gorenne I, Kumar S, Gray K, et al. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation. 2013; 127: 386-96.
45. Durand E, Scoazec A, Lafont A, et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation. 2004; 109: 2503-6.
46. Speidl WS, Katsaros KM, Kastl SP, et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis. 2010; 208: 285-9.
47. Köhl J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr Opin Mol Ther. 2006; 8: 529-38.